FDA clears Pfizer's Xeljanz for inflammatory bowel disease

(Reuters) - The U.S. Food and Drug Administration said on Wednesday that it had approved Pfizer Inc's drug, Xeljanz, to treat adults with moderate-to-severe active ulcerative colitis.